PARIS, FRANCE: Valneva SE, a company that specializes in vaccines, has sold a PRV (Priority Review Voucher) received from the U.S. FDA (Food and Drug Administration) for €95 million ($103 million).
The PRV was given to Valneva in November 20231 after the U.S. FDA approved its chikungunya vaccine, IXCHIQ®, which is the first of its kind in the world. The vaccine is a single shot that protects people 18 years and older from the chikungunya virus, which causes a painful and debilitating disease.
Valneva plans to use the money from the PRV sale to fund its research and development projects, such as its Lyme disease vaccine, more trials for its chikungunya vaccine, and new vaccines for other diseases that need solutions.
Valneva’s CEO, Thomas Lingelbach, said, “This extra funding will help us continue to develop our pipeline of vaccines. We are proud of our chikungunya vaccine, and we want to create more vaccines that can improve people’s health and well-being.”
The PRV program is a way for the U.S. FDA to reward companies that make products for tropical diseases. The program aims to motivate companies to develop new drugs and biologics for these diseases. Companies that get a PRV can use it to get a faster review for another product, or sell it or transfer it to someone else.
Valneva SE to supply one million Covid vaccine VLA2001 to Bahrain